Literature DB >> 17615144

Early lethality in Hyp mice with targeted deletion of Pth gene.

Xiuying Bai1, Dengshun Miao, David Goltzman, Andrew C Karaplis.   

Abstract

Although increased circulating levels of PTH with mild hypocalcemia has been reported in Hyp mice, hyperparathyroidism in X-linked hypophosphatemic rickets is postulated to arise from the standard use of phosphate salts, which induce chronic stimulation of PTH secretion. In this study, we sought to examine the role of PTH in the metabolic derangements associated with Hyp by generating hemizygous hypophosphatemic (Hyp/Y) mice homozygous for the Pth-null allele (Pth(-/-);Hyp/Y). Early postnatal lethality was observed in the Pth(-/-);Hyp/Y mice. Within the first 6 h, postpartum serum phosphorus increased to levels comparable to those in the Pth(-/-) mice, whereas in Hyp mice, it decreased during the first 48 h after birth. Serum calcium concentration started low after birth and remained reduced in both Pth(-/-);Hyp/Y and Pth(-/-) mice although more profoundly so in the former group, whereas in Hyp/Y mice, the levels were initially lower than but reached wild-type levels by 24 h. Circulating PTH levels in Hyp/Y mice were higher than wild-type levels throughout the first 48 h after birth and continued to be so well into adulthood. Twice-daily administration of PTH 1-34 to Pth(-/-);Hyp/Y newborn mice increased serum calcium levels and prevented their early demise. The findings here indicate that the cause of death in the Pth(-/-);Hyp/Y mice is severe hypocalcemia. A potential role for fibroblast growth factor 23 in promoting secondary hyperparathyroidism by suppressing renal 25-hydroxyvitamin D(3)-1alpha-hydroxylase (Cyp27b1) activity while increasing that of renal 25-hydroxyvitamin D(3) 24-hydroxylase (Cyp24) is proposed. Hyperparathyroidism, therefore, is an integral component in the pathophysiology of Hyp, and likely X-linked hypophosphatemic rickets and serves to prevent severe hypocalcemia in mice and perhaps in patients afflicted with the disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17615144     DOI: 10.1210/en.2007-0243

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

1.  Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study.

Authors:  Thomas O Carpenter; Elizabeth A Olear; Jane H Zhang; Bruce K Ellis; Christine A Simpson; David Cheng; Caren M Gundberg; Karl L Insogna
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

2.  FGF23 Is Not Required to Regulate Fetal Phosphorus Metabolism but Exerts Effects Within 12 Hours After Birth.

Authors:  Yue Ma; Beth J Kirby; Nicholas A Fairbridge; Andrew C Karaplis; Beate Lanske; Christopher S Kovacs
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

3.  Neither absence nor excess of FGF23 disturbs murine fetal-placental phosphorus homeostasis or prenatal skeletal development and mineralization.

Authors:  Yue Ma; Manoharee Samaraweera; Sandra Cooke-Hubley; Beth J Kirby; Andrew C Karaplis; Beate Lanske; Christopher S Kovacs
Journal:  Endocrinology       Date:  2014-03-06       Impact factor: 4.736

Review 4.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

5.  CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders.

Authors:  Xiuying Bai; Dengshun Miao; Sophia Xiao; Dinghong Qiu; René St-Arnaud; Martin Petkovich; Ajay Gupta; David Goltzman; Andrew C Karaplis
Journal:  J Clin Invest       Date:  2016-01-19       Impact factor: 14.808

6.  Alterations in phosphorus, calcium and PTHrP contribute to defects in dental and dental alveolar bone formation in calcium-sensing receptor-deficient mice.

Authors:  Wen Sun; Weiwei Sun; Jingning Liu; Xichao Zhou; Yongjun Xiao; Andrew Karaplis; Martin R Pollak; Edward Brown; David Goltzman; Dengshun Miao
Journal:  Development       Date:  2010-02-11       Impact factor: 6.868

Review 7.  Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

8.  Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.

Authors:  Tamara Isakova; Orlando Gutierrez; Anand Shah; Lorraine Castaldo; Julie Holmes; Hang Lee; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

9.  Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model.

Authors:  Teruyo Nakatani; Mutsuko Ohnishi; M Shawkat Razzaque
Journal:  FASEB J       Date:  2009-07-07       Impact factor: 5.191

Review 10.  Insights from genetic disorders of phosphate homeostasis.

Authors:  Marta Christov; Harald Jüppner
Journal:  Semin Nephrol       Date:  2013-03       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.